TerminatedPhase 2NCT00109889
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
Studying Plasmacytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Andrzej J. Jakubowiak, MD, PhDUniversity of Michigan Rogel Cancer Center
- Intervention
- magnetic resonance imaging(procedure)
- Enrollment
- 2 target
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2005 – 2007
Study locations (26)
- Mobile Infirmary Medical Center, Mobile, Alabama, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- CCOP - Montana Cancer Consortium, Billings, Montana, United States
- Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States
- Northern Rockies Radiation Oncology Center, Billings, Montana, United States
- St. Vincent Healthcare, Billings, Montana, United States
- Billings Clinic Cancer Center, Billings, Montana, United States
- Deaconess Billings Clinic - Downtown, Billings, Montana, United States
- Bozeman Deaconess Cancer Center, Bozeman, Montana, United States
- St. James Community Hospital, Butte, Montana, United States
- Big Sky Oncology, Great Falls, Montana, United States
- Sletten Regional Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States
- St. Peter's Hospital, Helena, Montana, United States
- +11 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00109889 on ClinicalTrials.govOther trials for Plasmacytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07115667Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow InfiltrationInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06863584SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II TrialSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT06429150Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT05248633Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaPeking Union Medical College Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT04174196A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT04166565Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseaseStichting European Myeloma Network
- ACTIVE NOT RECRUITINGPHASE3NCT02544308Trial of Immunomodulatory Therapy in High Risk Solitary Bone PlasmacytomaUniversity College, London